JBN Biotech ApS: Financial statements 2025
CVR: 40685693
Source: annual report 2025, Danish Business Authority
01/07/2024 – 30/06/2025
JBN Biotech ApS (CVR 40685693) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -22,188 and a net result of DKK -222,807 compared with DKK -263,330 the year before. Equity in the 2025 report amounted to DKK 34,941,304. The solvency ratio was 74.1%.
- Gross Profit
- DKK -22,188
- Profit/Loss
- DKK -222,807
- Equity
- DKK 34,941,304
- Total Assets
- DKK 47,146,455
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | -22 t. | -223 t. | 34.9 mio. | 0 |
| 2024 | - | -20 t. | -263 t. | 35.2 mio. | 0 |
| 2023 | - | -25 t. | -184 t. | 35.4 mio. | 0 |
| 2022 | - | -16 t. | 31.9 mio. | 35.6 mio. | 0 |
| 2021 | - | -16 t. | 4.3 mio. | 3.7 mio. | 0 |
Official annual report
How creditworthy is JBN Biotech ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout JBN Biotech ApS
JBN Biotech ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2019. The company is registered under the industry Anden finansiel formidling i.a.n.. The management consists of Jens Bredal Nielsen. The company is owned by Jens Bredal Nielsen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -22,188 and a net result of DKK -222,807 compared with DKK -263,330 the year before. Equity in the 2025 report amounted to DKK 34,941,304.